Systems and methods for super-resolution optical imaging technologies and/or nanosensor-driven patient monitoring and/or treatment

Patent metadata

Field	Value
Publication number	US-2025303001-A1
Application number	US-202418977507-A
Country	US
Kind code	A1
Filing date	Dec 11, 2024
Priority date	Jun 23, 2017
Publication date	Oct 2, 2025
Grant date	—

Abstract

Described herein are systems and methods for intracellular imaging, assessment, and/or treatment of tissue before, during, and/or after surgical procedures using nanoparticles (e.g., less than 50 nanometers in diameter, e.g., photoswitchable nanoparticles) and/or a super-resolution microscope system. The present disclosure describes nanoparticles (e.g., nanosensors and photoswitchable nanoparticles) that are used to monitor and/or track changes in environmental conditions and/or analytes in the cellular microenvironment before, during, and/or after surgical procedures. The present disclosure also describes systems and methods that provide information related to the distribution and/or delivery of photoswitchable nanoparticles at super resolution (e.g., using super-resolution microscopy).

First claim

1 . A method for imaging, surgical navigation, and/or cancer treatment planning, the method comprising:
(a) intravenously administering to a subject a composition comprising one or more nanoparticles,
wherein each of the one or more nanoparticles operates as a nanosensor for one or more environmental conditions and/or analytes selected from the group consisting of reactive oxygen species (ROS), pH, pH perturbation, iron level, calcium, glutathione, leucine, glutamine, arginine, and other amino acid,
wherein each of the one or more nanoparticles has a diameter from about 1 nm to about 10 nm and comprises at least one photoluminescent reference dye and at least one photoluminescent sensory dye,
wherein the at least one photoluminescent reference dye exhibits a relatively constant photon emission and the at least one photoluminescent sensor dye exhibits different photon emissions depending on the one more environmental conditions and/or analytes, and wherein the at least one photoluminescent reference dye and the at least one photoluminescent sensor dye are separated in different compartments of the nanoparticle; and
wherein the one or more nanoparticles comprise a silica-based core and polyethylene glycol attached to the nanoparticle; and the at least one photoluminescent reference dye is within the silica-based core;
(b) exciting the photoluminescent dyes by one or more selected wavelengths of a multi-photon light source, (c) detecting a signal emitted by the photoluminescent reference dye and a signal emitted by the photoluminescent sensor dye after the one or more administered nanoparticles are localized within one or more subcellular compartments or structures, attached to cell surface receptors, and/or across a barrier;
wherein the signal emitted by the sensor dye is indicative of the one or more environmental conditions and/or analytes within a cancer cell or a tumor; and
(d) graphically rendering and identifying the administered one or more nanoparticles at a subcellular level via a processor of a computing device, wherein the identifying comprises counting individual nanoparticles.

2 . The method of claim 1 , wherein the nanoparticle comprises a pathway inhibitor and/or other immune modulator.

3 . The method of claim 1 , wherein each photoluminescent dye comprises an independently-detectable fluorophore.

4 . The method of claim 1 , wherein each dye emits light at a discrete detectable wavelength.

5 . The method of claim 1 , wherein the reference dye and the sensor dye are chemically different dyes.

6 .- 8 . (canceled)

9 . The method of claim 1 , further comprising:
(e) determining, via a processor of a computing device, a quantitative map of one or more members selected from the group consisting of tissue perfusion, tissue viability, oxygen/pH status, deep tissue, tumor volume, and treatment planning volumes for perioperative high-precision therapies, based on the detected signals.

10 .- 11 . (canceled)

12 . The method of claim 9 , wherein the map is determined by a ratio of the signal emitted by the sensor dye normalized by the signal emitted by the reference dye.

13 .- 32 . (canceled)

33 . The method of claim 1 , further comprising administering to the subject (i) one or more standard-of-care immune checkpoint blocking (ICB) antibodies and/or one or more small molecule inhibitors; or (ii) one or more standard-of-care anti-androgen receptor therapeutics and/or a hypoxia-activated prodrug.

34 . The method of claim 33 , further comprising monitoring responses of the subject to treatment by detecting one or more environmental conditions and/or analytes selected from the group consisting of reactive oxygen species (ROS), pH, pH perturbation, iron level, calcium, glutathione, leucine, glutamine, arginine, and other amino acid.

35 . (canceled)

36 . The method of claim 1 , wherein the identifying is (i) for assessment of nanoparticle delivery and/or trafficking and/or (ii) for nanosensor imaging of cancer metabolism and/or therapeutic response and/or progression and/or the one or more environmental conditions.

37 . (canceled)

38 . The method of claim 1 , comprising determining, based on the one or more nanoparticles, localized within one or more cells of the tissue of the subject, a dosing limit for drug delivery.

39 .- 44 . (canceled)

45 . The method of claim 1 , wherein the nanoparticles have an average diameter from about 5 nm to about 7 nm.

46 . The method of claim 1 , wherein the one or more nanoparticles comprise a member selected from the group consisting of C dots, C′ dots, srC′ dots, and iC′ dots.

47 . The method of claim 1 , wherein each of the one or more nanoparticles comprise from 1 to 60 targeting moieties, wherein the targeting moieties bind to receptors on tumor cells.

48 . The method of claim 1 , wherein each of the one or more nanoparticles comprises a drug attached via a linker moiety.

49 . (canceled)

50 . The method of claim 1 , wherein the detecting the signal is performed with super resolution impinging and/or confocal imaging.

51 . The method of claim 1 , wherein the method is performed before, during, and/or after a surgical procedure.

52 . The method of claim 1 , wherein the barrier is a tissue barrier, a mucosal barrier, an intestinal epithelial barrier, a blood-brain barrier, or a blood-tumor barrier,

Assignees

• Memorial Sloan Kettering Cancer Center
• Univ Cornell

Inventors

• Bradbury Michelle S
• Wiesner Ulrich
• Overholtzer Michael
• Abu-Rustum Nadeem R
• Madajewski Brian

Classifications

• A61K49/0093

  Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle · CPC title

• A61K49/0056

  Peptides, proteins, polyamino acids · CPC title

• A61K49/0043

  Fluorescein, used in vivo · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61B5/4848

  Monitoring or testing the effects of treatment, e.g. of medication · CPC title